Nature2mon
Treating skeletal pain: limitations of conventional anti-inflammatory drugs, and anti-neurotrophic factor as a possible alternative
Although treatment with anti-NGF antibodies did not seem to interfere with the bone healing process, as assessed by mechanical testing and histomorphometric analysis, 40 the potential role of ...
pharmaphorum2d
Pfizer/Lilly non-opioid pain drug hits mark in phase 3 trial
A filing is due next year, and at the moment Lilly and Pfizer look in a strong position in the race to get anti-NGF painkillers to market. Regeneron is developing its rival anti-NGF antibody ...
Medical Dialogues12d
Fasinumab significantly improves pain scores among difficult-to-treat patients of OA of knee or hip: study
Osteoarthritis (OA) causes significant musculoskeletal pain. The study by DiMartino et al assessed the efficacy and safety of ...
pharmaphorum7y
FDA fast-tracks Lilly/Pfizer pain drug amid opioid crisis
However there remains a safety question in connection with the drug: the anti-nerve growth factor (NGF) inhibitor was delayed for years because of safety fears that emerged during animal studies.